ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CDH3/MMAE Antibody-drug Conjugate BC3195

Also written as “BC3195” and “Drug: BC3195 for Injection”.

Its studies are mostly in Neoplasm Metastasis, led by Biocity Biopharmaceutics.

Drug pageAnti-CDH3/MMAE Antibody-drug Conjugate BC3195: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 5, 20263 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocity Biopharmaceutics33 open or runningphase 2since Mar 5, 2026Jul 13, 2023Apr 30, 2027phase 1 · NCT06548672

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2023First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT05957471 · 27 planned · China
  2. Jul 11, 2024Phase 1 study in Neoplasm MetastasisNCT06548672 · 148 planned · United States
  3. Mar 5, 2026Phase 2 study in Locally Advanced or Metastatic Solid TumorsPhase 2 reachedNCT07469774 · 111 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT06548672
  2. Dec 31, 2027Primary completion: phase 2 study in Locally Advanced or Metastatic Solid TumorsNCT07469774

TargetBeta

CDH3 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the human tumor-associated antigen (TAA) cadherin-3 (CDH3; placental cadherin; P-cadherin), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07469774Locally Advanced or Metastatic Solid Tumors · China2RecruitingDec 31, 2027111
NCT06548672Neoplasm Metastasis · United States1RecruitingApr 30, 2027148
NCT05957471Locally Advanced or Metastatic Solid Tumors · China1RecruitingJun 202527

How it is read

Names in the registry

  • “BC3195”, 2 entries
  • “Drug: BC3195 for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.